S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Michael Egholm, President and CEO of Standard Biotools Inc. (NASDAQ:LAB), recently sold 4,719 shares of the company’s common stock. The sale, which took place on May 21, 2025, was executed at an average price of $1.03 per share, totaling approximately $4,860. This transaction was made to satisfy tax withholding obligations following the vesting of restricted stock units (RSUs) granted earlier in March.
In a related transaction on May 20, 2025, Egholm disposed of 18,343 shares at a price of $1.05 per share, amounting to $19,260. These shares were also withheld to cover tax obligations stemming from the vesting of RSUs granted in May 2024.
Following these transactions, Egholm holds 2,751,780 shares of Standard Biotools, maintaining a significant stake in the company. The company has shown strong revenue growth of 33.86% over the last twelve months. For deeper insights into Standard Biotools’ valuation and 12 additional ProTips, visit InvestingPro.
In other recent news, Standard Biotools Inc. reported a net loss for the first quarter of 2025, with earnings per share (EPS) of -$0.07, missing the analyst forecast of -$0.06. The company’s revenue for the quarter totaled $40.8 million, falling short of the projected $45.6 million, marking a 10% year-over-year decline. The decrease in revenue was primarily due to a 16% drop in both consumables and services revenue, although instrument revenue increased by 24%. Standard Biotools has set its full-year revenue guidance for 2025 between $165 million and $175 million. The company aims to achieve adjusted EBITDA positive results by 2026 and is exploring strategic mergers and acquisitions. Despite the challenges, CEO Michael Egholm emphasized the company’s focus on long-term growth and profitability. CFO Alex Kim highlighted the company’s strong cash position of $261 million with no material debt. Analysts from firms such as TD Cowen and Jefferies engaged with the company during the earnings call, inquiring about demand trends and strategic partnerships, including the collaboration with Illumina (NASDAQ:ILMN).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.